SureTrader
Home > Boards > US OTC > Biotechs >

Oxford BioMedica PLC (OXBDF)

OXBDF RSS Feed
Add OXBDF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/20/2018 4:51:02 AM - Followers: 6 - Board type: Free - Posts Today: 1

Oxford BioMedica PLC (OXBDF) 
 
Trades In UK as (OXB.L)
  
  
Company website

UK company traded on grey's in US

 

 
Company Address:
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom - Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001

 
Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ?wet? age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
 
Management
 
Partnerships 
 
Financial Reports:  http://www.oxfordbiomedica.co.uk/financial-reports/
 
Investor Contacts:  http://www.oxfordbiomedica.co.uk/investor-contacts/
 
 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 
 
 
 
 
 
SureTrader
OXBDF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#616   In April we announced an agreement to acquire marcusl2 04/20/18 04:51:02 AM
#615   https://seekingalpha.com/article/4164128-novartis-ag-2018-q1-results-earnings-ca marcusl2 04/19/18 04:35:08 PM
#614   More work and royalties for OXB marcusl2 04/19/18 04:31:03 PM
#613   Kudos! On the grey sheet with a JUST 10-11-12 04/16/18 10:53:40 PM
#612   Could it be that Novartis is negotiating to georgejjl 04/16/18 09:42:28 PM
#611   OXBDF up 117.88% today Monday April 16, 2018 georgejjl 04/16/18 08:11:20 PM
#610   Vulpes buy marcusl2 04/11/18 03:44:10 PM
#609   Pancreatic cancer therapy with combined mesothelin-redirected chimeric antige georgejjl 04/10/18 08:33:18 PM
#608   Novartis bets big on gene therapy with $8.7 georgejjl 04/09/18 07:59:56 PM
#607   Advances in Cancer Immunotherapy for Lymphoma georgejjl 04/06/18 01:46:21 PM
#606   Great stuff thanks George. A deal for it marcusl2 04/04/18 05:11:27 AM
#605   Click and read the pdf file georgejjl 04/03/18 07:50:54 PM
#604   Preclinical Assessment of CAR T-Cell Therapy Targeting the georgejjl 04/03/18 07:39:15 PM
#603   The 5T4 oncofetal glycoprotein does not act as georgejjl 04/03/18 07:35:12 PM
#602   The breast cancer antigen 5T4 interacts with Rab11, georgejjl 04/03/18 07:32:27 PM
#601   more than 2 companies very interested in Prosavin marcusl2 03/20/18 04:13:27 PM
#600   http://www.hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-do marcusl2 03/20/18 05:04:28 AM
#599   14:05 Advances in CAR-T Therapy for Chronic Lymphocytic marcusl2 03/19/18 03:56:53 PM
#598   HTTPS://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358667/ In Brief marcusl2 03/19/18 03:55:25 PM
#597   09:35 Design of a Highly Efficacious CAR Targeting marcusl2 03/19/18 03:55:00 PM
#596   Carl June "Cancer therapy poised for rapid advances, marcusl2 03/14/18 11:51:37 AM
#595   Marcus.. Can you update TOTAL OS on here? Chaka 03/12/18 02:09:21 PM
#594   M&G is an investment manager in the UK marcusl2 03/12/18 06:10:56 AM
#593   Foret UK PPS ATM. Chaka 03/11/18 03:29:51 PM
#592   Oxford Biomedica announces placing to inject £20.5m for expansion georgejjl 03/09/18 08:03:48 PM
#591   Optogenetic Tractography for anatomo-functional characterization of cortico-subc georgejjl 03/09/18 06:09:57 PM
#590   The Placing has been supported by a range marcusl2 03/09/18 04:49:08 PM
#589   That was a surprise at 3pm! marcusl2 03/09/18 04:48:36 PM
#588   University of Pennsylvania, told HemOnc Today. “I would marcusl2 03/09/18 04:47:52 PM
#587   Oxford BioMedica PLC (LON:OXB): Is Breakeven Near? georgejjl 03/08/18 07:44:55 AM
#586   Gene therapy was a boy’s last chance to marcusl2 03/05/18 09:09:43 AM
#585   http://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-docume marcusl2 02/28/18 04:30:28 AM
#584   So I would guess that our 2nd undisclosed marcusl2 02/25/18 05:10:29 AM
#583   So in Haemophilia Lenti should be better than marcusl2 02/23/18 05:42:17 PM
#582   Helen Maunder, PhD marcusl2 02/23/18 10:37:17 AM
#581   From LSE. Nice to hear marcusl2 02/21/18 06:30:24 AM
#580   Safety and efficacy of OXB-202, a Genetically-Engineered Tissue georgejjl 02/19/18 11:52:36 PM
#579   Celgene and Bluebird Bio georgejjl 02/19/18 07:57:27 AM
#578   https://endpts.com/bioverativ-inks-100m-gene-therapy-deal-with-oxford-biomedica/ marcusl2 02/18/18 04:33:20 AM
#577   He reckons Novartis` Cart BCMA has cured him marcusl2 02/16/18 05:58:40 PM
#576   2018 is predicted to be profitable for Oxford BioMedica georgejjl 02/16/18 09:06:33 AM
#575   Oxford BioMedica marcusl2 02/16/18 04:22:52 AM
#574   HTTPS://www.thetimes.co.uk/article/oxford-biomedica-clinches-second-gene-therapy marcusl2 02/16/18 04:21:59 AM
#573   $100 million here and $100 million there can georgejjl 02/15/18 08:49:36 PM
#572   Expect more from the Novartis/Oxford BioMedica collaboration georgejjl 02/15/18 07:59:03 PM
#571   Under the terms of the agreement, Oxford BioMedica marcusl2 02/15/18 04:33:31 AM
#570   Prosavin http://www.acnr.co.uk/wp-content/uploads/2014/08/ja-sheila-roy.gif Partici georgejjl 02/14/18 08:46:40 PM
#569   HTTPS://www.youtube.com/watch?v=Dh_helDPpIg So the Chinese study treated earl marcusl2 02/13/18 08:08:05 AM
#568   Mantle Cell Lymphoma marcusl2 02/09/18 06:01:26 AM
#567   CART 5T4 combined with IL-12 plus doxorubicinn could georgejjl 02/01/18 07:08:29 PM
PostSubject